The DOI matches its Crossref record.
Functional Characterization of an Endosome-disruptive Peptide and Its Application in Cytosolic Delivery of Immunoliposome-entrapped Proteins
Open accessAbstract
Antibody-directed liposomes (immunoliposomes) are frequently used for targeted drug delivery. However, delivery of large biotherapeutic molecules (i.e. peptides, proteins, or nucleic acids) with immunoliposomes is often hampered by an inefficient cytosolic release of entrapped macromolecules after target cell binding and subsequent endocytosis of immunoliposomes. To enhance cytosolic drug delivery from immunoliposomes present inside endosomes, a pH-dependent fusogenic peptide (diINF-7) resembling the NH(2)-terminal domain of influenza virus hemagglutinin HA-2 subunit was used. Functional characterization of this dimeric peptide showed its ability to induce fusion between liposome membranes and leakage of liposome-entrapped compounds when exposed to low pH. In a second series of experiments, diINF-7 peptides were encapsulated in immunoliposomes to enhance the endosomal escape of diphtheria toxin A chain (DTA), which inhibits protein synthesis when delivered into the cytosol of target cells. Immunoliposomes targeted to the internalizing epidermal growth factor receptor on the surface of ovarian carcinoma cells (OVCAR-3) and containing encapsulated DTA did not show any cytotoxicity toward OVCAR-3 cells. Cytotoxicity was only observed when diINF-7 peptides and DTA were co-encapsulated in the immunoliposomes. Thus, diINF-7 peptides entrapped inside liposomes can greatly enhance cytosolic delivery of liposomal macromolecules by pH-dependent destabilization of endosomal membranes after cellular uptake of liposomes.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
Recent advances with liposomes as pharmaceutical carriers
Torchilin, V. P. (2005) · Nature Reviews Drug Discovery · doi:10.1038/nrd1632 · Cited by 5,282
Endosomal escape pathways for delivery of biologicals
Varkouhi, A. K., Scholte, M., Storm, G., & Haisma, H. J. (2011) · Journal of Controlled Release · doi:10.1016/j.jconrel.2010.11.004 · Cited by 1,561
“The presence of this peptide, efficiently enhanced the endosomal escape when used in complex with lipid carriers for siRNA [54] and protein [55] delivery and also in complex with polymeric vectors for gene delivery purposes [56–58].”
BackgroundSelf-citationCanton, I., & Battaglia, G. (2012) · Chemical Society Reviews · doi:10.1039/c2cs15309b · Cited by 936
Viral and nonviral delivery systems for gene delivery
Nayerossadat, N., Maedeh, T., & Ali, P. (2012) · Advanced Biomedical Research · doi:10.4103/2277-9175.98152 · Cited by 858
Targeted pharmaceutical nanocarriers for cancer therapy and imaging
Torchilin, V. P. (2007) · The AAPS Journal · doi:10.1208/aapsj0902015 · Cited by 762
Basics and Recent Advances in Peptide and Protein Drug Delivery
Bruno, B. J., Miller, G. D., & Lim, C. S. (2013) · Therapeutic Delivery · doi:10.4155/tde.13.104 · Cited by 754
Dendritic-cell immunotherapy: from ex vivo loading to in vivo targeting
Tacken, P. J., de Vries, I. J. M., Torensma, R., & Figdor, C. G. (2007) · Nature Reviews Immunology · doi:10.1038/nri2173 · Cited by 750
Lipid-Based Drug Delivery Systems in Cancer Therapy: What Is Available and What Is Yet to Come
Yingchoncharoen, P., Kalinowski, D. S., & Richardson, D. R. (2016) · Pharmacological Reviews · doi:10.1124/pr.115.012070 · Cited by 744
Subcellular targeting strategies for drug design and delivery
Rajendran, L., Knölker, H.-J., & Simons, K. (2010) · Nature Reviews Drug Discovery · doi:10.1038/nrd2897 · Cited by 708
Hatakeyama, H., Akita, H., & Harashima, H. (2011) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2010.09.001 · Cited by 645
Chitosan-based delivery systems for protein therapeutics and antigens
Amidi, M., Mastrobattista, E., Jiskoot, W., & Hennink, W. E. (2010) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2009.11.009 · Cited by 620
Self-citationMultifunctional and stimuli-sensitive pharmaceutical nanocarriers
Torchilin, V. (2009) · European Journal of Pharmaceutics and Biopharmaceutics · doi:10.1016/j.ejpb.2008.09.026 · Cited by 583
“Combination of immunoliposome and endosome-disruptive peptide improves the cytosolic delivery of the liposomal drug, increases cytotoxicity, and opens new approach to constructing targeted liposomal systems as shown with diphtheria toxin A chain incorporated together with pH-dependent fusogenic peptide diINF-7 into li…”
BackgroundPassive and Active Drug Targeting: Drug Delivery to Tumors as an Example
Torchilin, V. P. (2010) · Handbook of Experimental Pharmacology · doi:10.1007/978-3-642-00477-3_1 · Cited by 573
Delivery of Therapeutic Proteins
Pisal, D. S., Kosloski, M. P., & Balu-Iyer, S. V. (2010) · Journal of Pharmaceutical Sciences · doi:10.1002/jps.22054 · Cited by 532
Biodegradable nanoparticles for cytosolic delivery of therapeutics
VASIR, J., & LABHASETWAR, V (2007) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2007.06.003 · Cited by 526
“Recently, liposomes have been prepared with novel pH-sensitive lipids and synthetic fusogenic peptides either encapsulated [6,7] or incorporated in lipid bilayers [8-10].”
BackgroundOn the formulation of pH-sensitive liposomes with long circulation times
Simões, S. (2004) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2003.10.038 · Cited by 483
Tat peptide-mediated intracellular delivery of pharmaceutical nanocarriers
Torchilin, V. P. (2008) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2007.10.008 · Cited by 449
Erazo-Oliveras, A., Muthukrishnan, N., Baker, R., Wang, T.-Y., & Pellois, J.-P. (2012) · Pharmaceuticals · doi:10.3390/ph5111177 · Cited by 384
Peptide and protein drug delivery to and into tumors: challenges and solutions
Torchilin, V. P., & Lukyanov, A. N. (2003) · Drug Discovery Today · doi:10.1016/s1359-6446(03)02623-0 · Cited by 363
Drug delivery from gelatin-based systems
Foox, M., & Zilberman, M. (2015) · Expert Opinion on Drug Delivery · doi:10.1517/17425247.2015.1037272 · Cited by 360
Palanikumar, L., Al-Hosani, S., Kalmouni, M., Nguyen, V. P., Ali, L., Pasricha, R., Barrera, F. N., & Magzoub, M. (2020) · Communications Biology · doi:10.1038/s42003-020-0817-4 · Cited by 360
Intracellular delivery of nanomaterials: How to catch endosomal escape in the act
Martens, T. F., Remaut, K., Demeester, J., De Smedt, S. C., & Braeckmans, K. (2014) · Nano Today · doi:10.1016/j.nantod.2014.04.011 · Cited by 340
Torchilin, V. P. (2012) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2012.09.031 · Cited by 332
pH-Sensitive liposomes-principle and application in cancer therapy
Karanth, H., & Murthy, R. S. R. (2007) · Journal of Pharmacy and Pharmacology · doi:10.1211/jpp.59.4.0001 · Cited by 294
Polyelectrolyte microcapsules for biomedical applications
De Geest, B. G., De Koker, S., Sukhorukov, G. B., Kreft, O., Parak, W. J., Skirtach, A. G., Demeester, J., De Smedt, S. C., & Hennink, W. E. (2009) · Soft Matter · doi:10.1039/b808262f · Cited by 289
Investigating the pharmacodynamic durability of GalNAc–siRNA conjugates
Brown, C. R., Gupta, S., Qin, J., Racie, T., He, G., Lentini, S., Malone, R., Yu, M., Matsuda, S., Shulga-Morskaya, S., et al. (2020) · Nucleic Acids Research · doi:10.1093/nar/gkaa670 · Cited by 285
Endosomal escape of RNA therapeutics: How do we solve this rate-limiting problem?
Dowdy, S. F. (2023) · RNA · doi:10.1261/rna.079507.122 · Cited by 171
Metadata
- Authors
- Mastrobattista, E., Koning, G. A., van Bloois, L., Filipe, A. C. S., Jiskoot, W., & Storm, G.
- Venue
- Journal of Biological Chemistry
- Publisher
- Elsevier BV
- Published
- 2002-07
- Volume
- 277
- Issue
- 30
- Pages
- 27135-27143
- ISSN
- 0021-9258 (ISSN-L)
- OpenAlex
- W2027962832
- Cited by
- 173
- References
- 0
- FWCI
- 3.83
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.